GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

OPKO Health, Inc. (NASDAQ: OPK) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 25, the company, in partnership with Entera Bio Ltd., announced that new data for ...

More than 100 new laws will go into effect in Florida on July 1, with everything from animal abuse to education, state parks ...

Wegovy, a weight loss drug which reduces cardiovascular risks in obese individuals, launched in India on June 24. Experts ...

Even after dropping 1,300 bills to focus on the budget, the Florida Legislature passed more than 100 new laws that start July ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 ...

Glucagon-like peptide 1 receptor (GLP-1R) agonists have been detailed in a Fortvita Biologics Inc. patent. They are reported to be useful for the treatment of arthritis, coronary heart diseases, ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly one-quarter of their body weight in early trials.

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...